UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
20.11
+0.91 (4.74%)
At close: Aug 13, 2025, 4:00 PM
19.84
-0.27 (-1.35%)
Pre-market: Aug 14, 2025, 8:51 AM EDT
UroGen Pharma Revenue
UroGen Pharma had revenue of $24.22M in the quarter ending June 30, 2025, with 10.83% growth. This brings the company's revenue in the last twelve months to $94.24M, up 10.85% year-over-year. In the year 2024, UroGen Pharma had annual revenue of $90.40M with 9.29% growth.
Revenue (ttm)
$94.24M
Revenue Growth
+10.85%
P/S Ratio
10.09
Revenue / Employee
$401,013
Employees
235
Market Cap
930.37M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 90.40M | 7.69M | 9.29% |
| Dec 31, 2023 | 82.71M | 18.36M | 28.52% |
| Dec 31, 2022 | 64.36M | 16.32M | 33.96% |
| Dec 31, 2021 | 48.04M | 36.24M | 307.17% |
| Dec 31, 2020 | 11.80M | 11.78M | 65,450.00% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
URGN News
- 5 days ago - UroGen Pharma Ltd. (URGN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 7 days ago - UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 9 days ago - UroGen Announces 24-Month Duration of Response of 72.2% from the Pivotal Phase 3 ENVISION Trial of ZUSDURI, the First and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer - GlobeNewsWire
- 16 days ago - UroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025 - GlobeNewsWire
- 17 days ago - UroGen Announces Publication of Phase 3b Study Results Demonstrating the Feasibility of Home Instillation of ZUSDURI™ for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer in Reviews in Urology - GlobeNewsWire
- 24 days ago - UroGen Announces Five-Year Long-Term Extension Study of the OPTIMA II Trial Demonstrates Long-Term Durability of Response to ZUSDURI™ in Patients with Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer - GlobeNewsWire
- 5 weeks ago - UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer - GlobeNewsWire
- 2 months ago - URGN SHAREHOLDER REPORT: UroGen Pharma Ltd. was Sued for Fraud – Investors with Losses are Notified to Contact BFA Law by July 28 Court Deadline (NASDAQ:URGN) - GlobeNewsWire